Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.

ABSTRACT:

Background/aim

The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting agent has achieved approval. To add insight into potential response to mivebresib (ABBV-075), a broadspectrum BET inhibitor, co-clinical modeling of individual patient biopsies was conducted in the context of a Phase I trial in acute myeloid leukemia (AML).

Materials and methods

Co-clinical modeling involves taking the patient's biopsy and implanting it in mice with limited passage so that it closely retains the original characteristics of the malignancy and allows comparisons of response between animal model and clinical data. Procedures were de

SUBMITTER: Albert DH 

PROVIDER: S-EPMC9301399 | biostudies-literature | 2022 Jul-Aug

REPOSITORIES: biostudies-literature